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PREFACE
Summarized in this report is information pertaining to the SEP and 
information received from health officials, university investigators 
and other pertinent sources. Much of the information is preliminary. 
It is intended primarily for the use of those with responsibility for 
disease control activities. Anyone desiring to quote this report 
should contact the original investigator for confirmation and inter­
prêtât ion.
Contributions to the Report are aost welcome*
Please address tot National Communicable Disease Center
Atlanta, Georgia 30333
Attn: Chief, Smallpox Eradication Program
National Communicable Disease Center David J. Sencer, M . D . , Chief
Smallpox Eradication Program J. Donald Millar, M.D., Chief
Statistical Activities, SEP Donald L. Eddins, B.S., Chief
INTRODUCTION
In May 1965, President Johnson said "This government is ready to work with other 
interested countries to see to it that smallpox is a thing of the past by 1975."
To begin to implement this pledge, the U.S. Public Health Service and the U.S. 
Agency for International Development in coordination with the World Health Organi­
zation formulated plans for a 19-country program of smallpox eradication (and 
measles control) in West and Central Africa. In January of 1966, the Smallpox 
Eradication Program (SEP) was organized at NCDC from the old Smallpox Unit, Epi­
demiology Branch, to direct the 19-country West African Program as well as to 
continue NCDC's responsibilities for preventing the re-establishment of smallpox 
in the USA. Concurrent with the development of the West African Program, seven 
intermittent reports under the title "West African Smallpox Eradication/Measles 
Control Program Surveillance Report" have been issued since July 1966 providing 
demographic and morbidity and mortality data for the countries in the program.
In addition, beginning in December 1966, four "Status Reports" were issued sum­
marizing technical and logistical information for those immediately concerned 
with the West African Program.
With this issue, SEP inaugurates several changes including a new cover, a new 
name, and most important, a new scope. While primary emphasis will continue to 
be on the surveillance of smallpox (and measles in West Africa), the Report will not 
be limited to surveillance information. An attempt will be made to include com­
ments on the methodology and problems of smallpox eradication as reported from 
workers in the field in Africa and elsewhere. From time to time, information on 
anti-smallpox activities in the U.S. and other non-endemic countries will be 
included as will data on the occurrence of complications of vaccination. The 
Chief, Smallpox Eradication Program welcomes all comments, critical or otherwise, 
of the SEP Report and warmly invites submission of any information which may be 
of interest to those committed to smallpox eradication.
II. SMALLPOX SURVEILLANCE
A. Smallpox Surveillance in the United States - First Annual Review. 1966
Although the last confirmed cases of smallpox in the USA occurred in 1949*, 
NCDC maintains a continuing national vigilance for introduced smallpox. In 
1966, NCDC provided clinical, epidemiological, and laboratory assistance to 
the States in the diagnosis of 46 cases of suspicious vesicular disease.
In 14 instances (involving 16 patients*) the Smallpox Eradication Program con­
ducted an epidemiological appraisal; in 11 instances (involving 13 patients) 
NCDC medical epidemiologists were sent to perform detailed field investiga­
tions of the incident.
Of the 16 patients, 8 had recently traveled overseas and 5 of these had been 
in smallpox epidemic or endemic regions during the 2-weeks prior to their 
arrival in the United States. In one instance contact had taken place in the 
United States between the patient and a visitor from Kenya. Smallpox Health 
Alert Notices had been issued by the Foreign Quarantine Program to each of 
the 5 at the port of entry; these were instrumental in stimulating all 5 to 
seek medical aid when their illnesses began.
In the remaining 30 cases, laboratory specimens from a variety of sources in
the States were referred to the Vesicular Disease Virus Laboratory for 
diagnosis.
The 46 cases studied were reported from 21 States and Puerto Rico (Figure 1).
The seasonal distribution of suspect smallpox cases is seen in Figure 2
which presents the number of specimens received by month for laboratory 
diagnosis. *
Specimens were subjected to one or more of the following tests depending 
upon the information available at the time the specimen was received: culture
in embryonated eggs; tissue culture (RU 1 human embryonic lung fibroblast 
and HEP-2 cell lines); agar gel diffusion; electron microscopy; and occasion­
ally the complement fixation test for antigen. Sera submitted for study were 
subjected to either CF or HAI antibody testing.
Of the 46 cases, smallpox was considered by the reporting authority as the pri
mary clinical diagnosis in 17. In two other cases, smallpox was included in
the differential diagnosis. In no instance was the diagnosis of smallpox con­
firmed. (Negative culture results on the chorioallantoic membrane in earh of 
three successive passages coupled with negative electron microscopic and agar 
gel diffusion tests were accepted as sufficient to rule out the presence of 
variola or vaccinia virus). In 7 of the 17 cases, a virus other than variola 
was identified as the etiologic agent.
Of all the U6 cases studied an etiologic agent was identified in 18 (39.1 
percent). In only five did the agent identified confirm the original clini­
cal diagnosis. In an additional 13 cases, agents were recovered confirming 
a diagnosis other than the primary clinical diagnosis; in 28 cases, no 
etiologic agent was identified (see Table 1).
Three patients in one family
Irons, J.V., et al: "Outbreak of Smallpox in the Lower Rio Grande Valley
of Texas in 1949," Amer. J. Pub. Hlth., 43.:25-29, Jan.-July 1953.
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The 18 agents detected were identified by means of 5 different laboratory tests 
Table 2 presents findings by agent and result of the various tests performed. 
Vaccinia virus where present was identified by all of the available diagnostic 
procedures; In contrast chlckenpox was Identified only by electron microscopy 
and serologic means.
In 13 casesi the referring clinical diagnosis was "vaccinia" or "vaccination 
reaction." Available clinical, epidemiological and laboratory data for these 
cases Is sumnarlzed In Table 3. Eleven of the patients had a history of ex­
posure to vaccinia either by vaccination or by contact with a vaccinated 
sibling within three weeks preceding onset of Illness. Etlologlc agents were 
Identified In the specimens from only 4 of these 13 patients: two suffered 
from vacclnlal Infections, In both cases exzema vaccinatum; varicella and 
herpes simplex were serologically identified In two additional patients. No 
agents were Identified In the remaining 9, a surprising finding particularly 
In patients with rash disease following vaccination.
Table 1. Laboratory Diagnosis In Cases of Vesicular Disease 
for which NCDC Assistance was Sought, 1966
Primary Clinical 
Dlaenosis







Smallpox, RO SP 0 7 7 10 17
Vaccinia, RO Vacc. 1 2 3 9 12
Varicella, RO V ar. 2 1 3 5 8
Herpes, RO herpes 2 1 3 2 5
Other* 0 2** 2 2 4
TOTAL 5(10.9%) 13(28.3%) 18(39.1%) 28(60.9%) 46(100%)
* Hepatitis -1; Impetlgo-1; Kaposls-1; Encephalltis-1 
** Coxsackie A-16-1 (Serology); Enterovlrus-1 (Electron Microscopy)
Table 2. Distribution of Laboratory Diagnosis by 
Agent and Test Result, 1966
Agent
Identifications Number Positive bv Test Performed
CAM T.C. Agar Gel EM Serology
Vaccinla 4 4/4 4/4 2/2 1/1 1/1
Varicella 7 0/3 0/4 0/2 2/5 6/7
Herpes 5 2/3 2 A N.D. 1/2 3/3
Coxsackie Ajg 1 0 0 N.D. N.D. 1
"Enterovirus" 1 N.D. 0 N.D. 1 0
TOTAL 18
N.D. = Not done
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Table 3. Results of Laboratory Studies in Cases with a





Diagnos is Vaccination History Spec imen Lab Tests Done Test Results
(6-0049) 6 M PVE 10 d. post vacc. Sera Serology Negative
(6-0250) 15 M ?vaccinia rash No vaccination Hx VF, slide FA Negative
(6-0321*) 15 F PVE Died 18 d. post vacc. Bra in CAM, rc Negative
(6-0374) 12 M ?vaccinia - HS No history vacc. Pust. Fid. CAM, TC, FA Negative
(6-0414) 6mos. F ?vaccinia rash Post vaccination Sera Serology Pos. for vari­
cella
(6-07U2) 4 M He rpe s-? vac c in ia Without vaccination SI ides Serology, TC Both Pos. 
herpes simplex
(6-0824) 43 M Vaccinia rash 10 d. post vacc. VF TC, CAM, Serol. Negative




CAM, TC, Serol. All positive 
vaccinia
(6-62) 4 M General vaccinia 7 d. post vacc. VF, sera, 
scab, slide
CAM, TC, Gel, 
Serol.
Negative
(6-63) 7 M General vaccinia 7 d. post vacc. VF, sera, 
scab, si ide
CAM, TC, Gel, 
Serol.
Negative
(6-68) 5 M Vaccinia inoculate 7 d. post sibling 
vacc.
Sera Serol. Negative
(6-94) 9 M ?vaccinia inoculate Lesion 9 d. post vacc. Smear CAM, TC Negative




CAM, TC Both pos. for 
vaccinia
* Fatal case
COMMENTS: 1) 11/13 had history of prior vaccination.
2) Vaccinia isolated by culture on CAM and TC twice; varicella was identified only by serology.
3) Serologic testing was negative for vaccinia Ab titers in the five patients from whom sera were submitted.
4) Both vaccinia isolates came from patients with exzema vaccinatum.
O  . . Q
The period of study in the laboratory from receipt of specimen to issue of 
final report averaged 5.3. weeks with a range of 3 to 20 weeks. Preliminary 
reports were issued at 6 hours and 72 hours on all cases suspected of being 
smallpox.
Encephalitis Cases
Of the 46 cases there were 7 described clinically as encephalitis, from which 
specimens were referred for laboratory diagnosis; these are listed in Table 4. 
Laboratory studies were generally inconclusive. The one vaccinia isolate 
(#6-2783) was sent for confirmation from a state laboratory; serologic testing 
was suggestive of herpes simplex infection in one case (#6-2671).
Table 4. Encephalitis Cases Submitted to the Vesicular Disease 
Virus Laboratory for Study, 1966
Identifi­
cation








6-0049 6 M Post vaccinal encepha­
litis
2 weeks No All negative
6-1562 7 M "Relapsing Varicella 
Encephalitis" two 
weeks after rash
3 weeks No All negative
6-2031 5 F Varicella encephalitis Unknown Yes ?Enterovirus by I
6-2783 lOwks. M ?Herpes encephalitis 3-4 days Yes Vaccinia from 
brain
6-2869 5 F Varicella encephalitis Unknown Yes All negative
6-2671 50 M Viral encephalitis patho­
logically diagnoses as 
herpes simplex
Unknown Yes Herpes simplex 
by serology
6-0321 15 F Post vaccinal encepha­
litis, no rash, onset 11 
days after vaccination
18 days Yes All negative
Of the 7, 5 cases ended fatally. The frequency of mention of varicella or 
herpes in the clinical diagnoses of patients with CNS disease in this series 
suggests that these agents may be more frequently associated with severe CNS 
disease than is commonly appreciated.
(Reported by Ronald R. Roberto, M.D., Chief, Domestic Operations Section, SEP, 
NCDC and John M. Noble, M.D., Acting Chief, Vesicular Disease Laboratory,
LP, NCDC.)
B. Current Trends of Smallpox Occurrence 
World-Wide
As illustrated in Figure 3 smallpox was a world-wide problem as late as 1945. 
More recently the extent of smallpox has been substantially reduced, and the 
disease is now confined to parts of Southeast Asia, South America and Sub­
Sahara Africa (Figure 3). This year considerable attention is focused on 
India which is experiencing a surgence of epidemic smallpox.
F IG U R E  3
W O R L D  WIDE SMALL P O X  ENDEMIC A R E A S -1955
WORLD-WIDE S M A L L P O X  ENDEMIC A R E A S -1965
O  » «=>
Endemic Area—1945 
No Data Reported to WHO
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The past twenty years* world-wide experience of smallpox is shown in Figure 4. 
Major epidemics occurred in 1951 with 482,218 reported cases and 1958 with 
302,477 reported cases. From 1959 through 1966 between 50,000 and 100,000 
cases per year were reported. Even though in the early part of 1967 much of 
India has experienced epidemic smallpox it appears likely that the total num­
ber of smallpox cases reported in the world this year will remain in the range 
of 50,000 to 100,000.
Reports received by the World Health Organization through May 18, 1967, show 
a total of 31,478 compared with 24,478 for the corresponding time period of
1966. This represents an increase of 28.6 percent. The number of reported 
smallpox cases by continent is shown in Table 5. For comparable time periods, 
a decrease of 18.4 percent is noted for Africa, the Americas are experiencing 
a slight decrease and Asia has an increase of 47.1 percent.
Table 5. Distribution of Reported Smallpox Cases by Continent 








* Compiled from WHO reports, January 1 - May 18, 1967 
** All United Kingdom Cases 
*** Imported cases: 2 Germany; 1 Czechoslovakia
The distribution by country of smallpox in Asia during comparable time periods 
for 1966 and 1967 is shown in Table 6. India accounts for 87.8 percent of 
the total number of cases occurring in Asia this year. During the similar 
period of time in 1966, India accounted for 86.7 percent of the cases.
Table 6. Reported Smallpox Cases during 







Ind ia 15204 22669
Other 2 52
TOTAL 17545 25810
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47 48 49 50 51 52 53 54 55 56 57 58 59 60 6'l 62 63 64 65 66
Y E A R
1 9 4 7 - 1 9 5 0 :  E p i d .  &  V i t a l  S t a t .  R e p o r t  4 (1  1 - 1 2 ) :  1 9 5 1 .
1 9 5 1 - 1 9 5 8 :  E p i d .  &  V i t o l  S ta » .  R e p o r t  1 7  ( 1 0 ) :  1 9 6 4 .
1 9 5 9 - 1 9 6 6 :  W H O  R e g i o n a l  O f f i c e  f o r  t h e  E a s t e r n  M e d i t e r r a n e a n  P u b l i c a t i o n  - 
" S m a l l p o x  E r a d i c a t i o n  P r o g r a m "  t o  b e  r e p o r t e d  a t  t h e  2 0 t h  W o r l d  H e a l t h  
A s s e m b l y .
India
Recently, data were published by the World Health Organization (Vol. 42, #19) 
showing the distribution oE smallpox cases by state and territory for the 
first quarter o£ 1967 Eor India. During this quarter a total of 19,728 cases 
were reported, an increase of 108 percent over the 9,471 cases reported during 
the comparable period of 1966. The case fatality ratios are 23.4 and 24.9 for 
the first quarters of 1967 and 1966, respectively.
The attack rates per 100,000 population by state and territory are given in 
Table 7. The attack rate for Maharashtra State, 24.15, is almost 6 times 
that of the nation as a whole (4.20). However, the attack rate of 28.21 Eor 
Bombay (Maharashtra State) does not diEEer Erom the overall State rate. The 
mfd-year 1965 population estimates show Maharashtra State with 9.1 percent oE 
the total population, yet 54.2 percent oE the smallpox cases this year have 
been reported from this State. Bihar State, with an attack rate of 6.13 has 
had 15.5 percent of this year’s reported cases; its population represents 10.6 
percent.
Figure 5 illustrates the weekly distribution of smallpox cases for Bombay 
through May 13. The peak of the epidemic occurred during the week of March 
26; however, the decline since the week of April 2 has been very gradual.
f i g u r e s
R E P O R T E D  S M A L L P O X  C A S E S .  B O M B A Y .  I N D I A  
J A N U A R Y  1 -  M A Y  13.  1967
SOURCE' W H O
EDITORIAL NOTE:
Readers will note that data shown for Asia for the first quarter of 1967 in 
Surveillance Report #7 are discrepant from data in this report; however, 
both represent official data released by WOO. Discrepancies are being queried 
and will be corrected as information is developed.
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Table 7. Reported Smallpox Cases*, India 
First Quarter, 1967
o










Andhra Pradesh State 380.93 485 1.27
Andaman & Nicobar Terr. 0.78 - -
Assam State 131.91 126 0.96
Bihar State 497.80 3054 6.13
Chandigarh T*»rr.) 
Haryana State ) 221.14 1010 4.57***
Punjab State ) 
Delhi Terr. 30.55 175 5.73
Goa, Damon & Diu Terr. NA 9 -
Gujarat State 225.28 364 1.62
Himachal Pradesh St. 14.56 38 2.61
Jammu & Kashmir St. 36.94 - -
Kerala State 183.57 142 0.77
Madhya Pradesh St. 351.03 647 1.84
Madras State 352.33 108 0.31
Maharashtra St. 428.26 10344 24.15
Manipur State 8.70 - -
Mysore State 254.00 330 1.30
Nagaland State 4.37 4 .92
Orissa State 188.01 165 .88
Pondicherry State NA - -
Rajasthan State 219.69 647 2.95
Tripura St. 13.89 98 7.06
Uttar Pradesh St. 763.09 1647 2.16
West Bengal St. 386.63 335 0.87
TOTAL 4693.46 19728 4.20
* Provisional data obtained from WHO Weekly Cpidenuological Record No. 19, 
dated May 12, 1967.
** Population Source: Am. J. Pub. Hlth., Vol. 56, No. 10, Oct. 1966.
Mid-year 1965 estimate.
*** Punjab State was divided into Chandigarh Territory, Haryana State






Despite smallpox outbreaks in Ghana, Guinea, Nigeria and Sierra Leone, Africa 
as a whole has experienced a decrease of 18.4 percent in the total reported 
cases of smallpox cases as compared with last year.
West and Central Africa
Notifications received through the World Health Organization of smallpox cases 
occurring within the Smallpox Eradication/Measles Control Program countries 
through May 3, total 3,788 cases for this year. An increase of 26.6 percent 
over the 2,993 cases reported during the same time period of 1966 is observed. 
This increase is due in part to the epidemic situations occurring in the coun­
tries mentioned above. With the development of the Smallpox Eradication 
Program for these 19 countries, intensified efforts toward better reporting, 
increased surveillance activities and a public awareness of overall program 
efforts through health education activities have almost certainly given rise 
to increased reporting of smallpox cases.
The distribution by country of this year's cases as compared with last year is 
shown in Table 8. Nigeria accounts for 59.6 percent of the reported cases in 
1967 compared with 65.4 percent of the 1966 cases.
Table 8. Reported Smallpox Cases in the West Africa
Smallpox Eradication/Measles Control Program Countries, 





Cumulative Number of Cases 
1966 1967
Cameroon January 31 1 1
C . A . R . * - -
Chad April 9 0 4(i)
Congo (B) * - -
Dahomey April 18 162 321
Gabon ★ - -
Gambia ★ - -
Ghana April 25 1 8
Gu inea February 25 3 27
Ivory Coast March 26 0 2
Liberia February 28 0 3
Mali April 13 146 89
Mauritania ★ - -
Niger April 21 631 847
Nigeria April 1 1959 2257
Senegal * - -
Sierra Leone April 1 64(i) 163(i)
Togo April 9 18 57
Upper Volta January 28 8 9
TOTAL 2993 3788
* No cases reported to WHO through May 3, 1967 
(i) Includes imported cases
Smallpox Surveillance - Nigeria
The Federal Government of Nigeria in April initiated publication of a 
"Nigerian Smallpox-Measles Program Surveillance Report" series. Included 
in the first issue were numbers of very pertinent comments on surveillance 
and reporting problems and the importance of these in epidemic control. We 
are pleased to reproduce parts of the Report (Vol. 1, No. 1) below:
Recognition of Smallpox Cases:
"Recent surveys in three separate areas of the Federation indicate that most 
people recognize the clinical disease of smallpox. It carries many names and 
its cause is often attributed to supernatural causes, but it is generally 
identified and feared. Certain mild and modified cases, especially when they 
coexist with chickenpox are difficult to diagnos. A diagnostic laboratory 
is being established in Lagos to assist in the diagnosis of difficult cases.
Reporting of Smallpox Cases:
"Although many recognized cases of smallpox are reported, some are deliberately 
hidden. In a recent survey of 600 non-reported cases by health authorities 
in Kano (Northern Region), results showed that most people felt nothing could 
be gained by reporting their afflictions. Education is needed to convince the 
people that reporting does lead to action which can protect the village from 
further cases of smallpox.
Action on Smallpox Cnses '■
"Action in the form of case isolation, case treatment and vaccination of con­
tacts of smallpox cases must follow reporting if epidemics are to be pre­
sented. The local dispenser who recognizes an introduced case of smallpox 
into his village and institutes appropriate action not only is preventing 
much suffering and disability in his village, but is also doing his part in 
the eradication of smallpox from Nigeria. Prompt action is the best stimulus 
towards improvement in reporting."
(Reported by E. 0. Smith, M.D., Director, Smallpox-Measles Unit, Federal 
Ministry of Health, Nigeria.)
III. ERADICATION NOTES
A. Provisional Vaccination Data - West Africa SE/MC Program
Provisional data compiled for the month of April show at least 1,528,721 
smallpox and 352,904 measles vaccinations were administered in the 19 coun­
try area. This brings the total number of vaccinations administered during 
January through April of this year to at least 4,178,788 doses of smallpox 
and 806,558 doses of measles. Table 9 shows these data by country.
o
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Table 9. Smallpox and Measles Vaccinations (provisional data) 
Administered by Country, January-April, 1967
Countrv
Smallpox Vaccinations Measles Vaccinations
Jan-March April Jan^April Jan-March April Jan-April
Cameroon 200,000 250,000 450,000 30,000 58,021 88,021
C.A.R. 80,046 30,513 110,559 18,348 9,124 27,472
Chad 87,185 NR 87,185+ 14,665 NR 14,665+
Congo (B) NR NR NR NR NR NR
Dahomey 0 108,311 108,311 0 27,968 27,968
Gagon 50,000 NR 50,000* 8,000 NR 8,000+
Gambia 0 0 0 0 0 0
Ghana 114,000 8,760 122,760 9,500 1,877 11,377
Guinea NR NR NR NR NR NR
Ivory Coast 330,005 173,853 503,858 68,635 22,400 91,035
Liberia NR NR NR NR NR NR
Mali 314,353 163,593 477,946 71,749 55,531 127,280
Mauritania 0 0 0 0 0 0
Niger 374,000 260,000 634,000 57,000 40,000 97,000
Nigeria 439,000 325,500 764,500 25,000 35,000 60,000
Senegal 0 0 0 0 0 0
Sierra I«one NR NR NR NR NR NR
Togo 161,478 65,691 227,169 57,017 23,867 80,884
Upper Volta 500,000 142,500 642,500 93,740 79,116 172,856
TOTAL 2.650.067 1.528.721 4.178.788+ 453.654 352.904 806.558+
NR = No report
B. Nigeria - Pilot Projects
In mid-April the National Meeting of the Nigerian Smallpox Eradication- 
Measles Control Program personnel was held in Lagos, at which Nigerian pilot 
projects were discussed. These have been carried out in each of the Regions 
and in Lagos.
The "coverage" (proportion of the population vaccinated) was determined by 
post campaign assessment surveys. "Take rates" (proportion of those inocu­
lated who developed "takes") were estimated in preschool children. Table 10 
presents coverage and "take rate" data for pilot programs in each of the 
regions.
Table 10. Pilot Project Assessment Data, Nigeria, 1967
Site (Region) Coverage(%) Take Rate*(%)
Abakallki, Urban (Eastern) 74.8 100.0
Abakaliki Rural (Eastern) 90.0 **
Igbo Ora & Eruwa (Western) 77.0 99.8
lyekovia District (Mid-Western ) 85.7 ‘ 95.4
Kano, Kudu Ward (Northern ) 72.0 -
Maroko (Lagos ) 88.2 100.0
Zaria City (Northern) 96.8 -
* In preschool children.
In Table 11 the average number of vaccinations per team day is given for 
seven pilot projects. The total number of hours involved during the vaccina­
ting is not available, thus, the hourly rate is not shown. The range of vac­
cinations per team day was 853 to 4056 with an overall average of 1425.








Abakaliki Urban (Eastern) 22 3123 43392 46515 2114
Abakaliki Rural (Eastern) 60 ★ 55750 55750 929
Igbo Ora & Eruwa (Western) 16 3389 24306 27695 1731
Iyekovia District (Midwestern) 26 3233 18956 22189 853
Kano (Kudu Ward)(Northern) 12 7996 40678 48674 4056
Maroko (Lagos) 8 1205 10704 11909 1489
Zaria City (Northern) 30 4175 30987 35162 1172
TOTAL 174 23121 224773 247894 1425
* Data not available.
In general the following comments are applicable to each of these pilot 
projects! vaccinating was unusually heavy soon after the "clinic" opened, 
tapered off at noon, and picked up again during the late afternoon; a 
vaccination team's performance is much dependent on the initiative of the 
team leader, whose enthusiasm is vital; some team members were unable to 
perform all of the minor repairs on the jet injectors; for flexibility, 
vaccinators and recorders should be trained to perform both job.«.
(Reported by E. 0. Smith, M.D., Director Smallpox-Measles Unit, Federal 
Ministry of Health, Nigeria)
IV. FEATURES FOR NEXT ISSUE
A preview of the July issue is offered for the reader's interest. It will feature 
presentations of laboratory data on smallpox in several South .American countries 
and a detailed report of the assessment of a mass urban-rural vaccination cam­
paign by survey techniques will be presented.
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